FDA Approves First-in-Class RAS Inhibitor for Metastatic Pancreatic Cancer

The FDA approved Rasonque (daraxonrasib) on August 26, 2026, as the first-in-class RAS inhibitor for adults with metastatic pancreatic adenocarcinoma. The decision provides a targeted treatment option for a patient population that has historically faced limited therapeutic alternatives.

Developed by Revolution Medicines, Inc., Rasonque is administered as a once-daily tablet. The drug targets the RAS protein, a primary driver of tumor growth in the majority of pancreatic cancers. In a clinical trial involving 500 adults, Rasonque improved median overall survival to 13.2 months, a significant increase over the 6.7 months observed with standard chemotherapy.

The Challenge of Pancreatic Cancer

Pancreatic adenocarcinoma is a particularly lethal malignancy, accounting for 90% to 95% of the approximately 67,000 new pancreatic cancer cases diagnosed in the U.S. each year. While it represents only about 3.2% of all cancer diagnoses, it maintains a disproportionately high death rate. This is largely due to the frequency of late-stage detection and the biological complexity of the tumors. For decades, researchers considered the RAS protein "undruggable," making the development of a successful inhibitor a long-standing goal in oncology.

Industry Implications

This approval marks a critical shift in the treatment of aggressive cancers. By successfully targeting the RAS protein, Rasonque proves that a previously unreachable biological target can be neutralized. This breakthrough is expected to pave the way for similar targeted therapies in other cancer types where KRAS mutations are prevalent, potentially moving the industry away from broad-spectrum chemotherapy toward more precise molecular interventions.

Acting FDA Commissioner Kyle Diamantas, J.D., stated that the approval provides a "critical new option" for patients facing an "extraordinarily difficult and historically hard-to-treat cancer." Angelo de Claro, M.D., director of the FDA’s Oncology Center of Excellence, added that the drug showed "unprecedented results" in an area of high unmet need.

Next Steps

Medical providers will now integrate Rasonque into treatment protocols for adults who have received at least one prior systemic therapy or those who are not candidates for multiagent systemic therapy. While the primary efficacy is established, clinicians will continue to monitor long-term outcomes and the potential for combination therapies to further extend survival rates.